High-dose oxytocin protocol cuts postpartum hemorrhage by 23% overall, 40% in vaginal births

Postpartum hemorrhage (PPH) remains a leading cause of maternal morbidity and mortality worldwide, often due to uterine atony. Current standard-of-care protocols for PPH prevention typically involve oxytocin administration during the third stage of labor to promote uterine contraction. However, optimal dosing strategies for oxytocin to maximize efficacy while minimizing side effects are still under investigation. This study addresses the clinical gap of whether a higher, more sustained oxytocin dose can further reduce PPH rates.

Researchers conducted a single-center quality-improvement study comparing PPH rates before and after implementing a new high-dose oxytocin protocol. The study included 2,674 births, with 1,309 in the pre-implementation phase and 1,365 in the post-implementation phase. The intervention involved high-dose oxytocin (60 units over 1 hour) compared to the standard-of-care oxytocin (30 units over 1 hour followed by 3.6 units over 1 hour) during the third stage of labor. The primary outcome was PPH, defined as quantitative blood loss of 1,000 mL or more. Secondary outcomes included total quantitative blood loss. Statistical analysis used Poisson regression for relative risks and quantile regression for median blood loss differences.

Implementation of the high-dose oxytocin protocol was significantly associated with a reduction in overall postpartum hemorrhage (PPH). The PPH rate decreased from 14.3% in the standard-dose group to 11.2% in the high-dose group, representing an adjusted relative risk (aRR) of 0.77 (95% CI, 0.64-0.93). This indicates a 23% reduction in PPH risk. Additionally, median quantitative blood loss was significantly lower in the high-dose group (396 mL [IQR 200-673 mL]) compared to the standard-dose group (444 mL [IQR 240-749 mL]), with an adjusted median difference of -43 mL (95% CI, -72 to -14 mL).